Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma in Medicare Patients

被引：0
|
作者：
Saam A. Mojtahed
Nicole R. Boyer
Saieesh A. Rao
Thomas F. Gajewski
Jennifer Tseng
Kiran K. Turaga
机构：
[1] University of Chicago,Pritzker School of Medicine, Division of Biological Sciences
[2] University of Chicago,Center for Health and the Social Sciences
[3] University of Chicago,Department of Pathology, Division of Biological Sciences
[4] The University of Chicago,Department of Surgery, Division of Biological Sciences
来源：
Annals of Surgical Oncology | 2021年 / 28卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：9039 / 9047
页数：8
相关论文
共 50 条
  • [1] Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma in Medicare Patients
    Mojtahed, Saam A.
    Boyer, Nicole R.
    Rao, Saieesh A.
    Gajewski, Thomas F.
    Tseng, Jennifer
    Turaga, Kiran K.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (13) : 9039 - 9047
  • [2] ASO Visual Abstract: Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage 3 Melanoma in Medicare Patients
    Saam A. Mojtahed
    Nicole R. Boyer
    Saieesh A. Rao
    Thomas F. Gajewski
    Jennifer Tseng
    Kiran K. Turaga
    [J]. Annals of Surgical Oncology, 2021, 28 : 576 - 576
  • [3] ASO Visual Abstract: Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage 3 Melanoma in Medicare Patients
    Mojtahed, Saam A.
    Boyer, Nicole R.
    Rao, Saieesh A.
    Gajewski, Thomas F.
    Tseng, Jennifer
    Turaga, Kiran K.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (SUPPL 3) : 576 - 576
  • [4] NIVOLUMAB-ADJUVANT THERAPY FOR RESECTED STAGE III-IV MELANOMA: A COST-EFFECTIVENESS ANALYSIS FOR SPAIN
    Presa, M.
    Soria, A.
    Oyaguez, I
    Espinosa, E.
    Echave, M.
    Berrocal, A.
    Manzano, J. L.
    Suarez Rodriguez, J.
    Polanco Sanchez, C.
    [J]. VALUE IN HEALTH, 2019, 22 : S457 - S457
  • [5] Cost-effectiveness of encorafenib with binimetinib in unresectable or metastatic BRAF-mutant melanoma
    Trouiller, Jean-Baptiste
    Nikolaidis, Georgios F.
    Macabeo, Berengere
    Meyer, Nicolas
    Gerlier, Laetitia
    Schlueter, Max
    Laramee, Philippe
    [J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2024, 25 (04): : 641 - 653
  • [6] Cost-effectiveness of immune checkpoint inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanoma
    Li, Si Ni
    Wan, Xiaomin
    Peng, Liu Bao
    Li, Ya Min
    Li, Jian He
    [J]. BMC HEALTH SERVICES RESEARCH, 2023, 23 (01)
  • [7] Cost-effectiveness of immune checkpoint inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanoma
    Si Ni Li
    Xiaomin Wan
    Liu Bao Peng
    Ya Min Li
    Jian He Li
    [J]. BMC Health Services Research, 23
  • [8] Cost-effectiveness of pembrolizumab as an adjuvant treatment for patients with resected stage IIB or IIC melanoma in Switzerland
    Favre-Bulle, Andrea
    Bencina, Goran
    Zhang, Shujing
    Jiang, Ruixuan
    Andritschke, Daniel
    Bhadhuri, Arjun
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 283 - 292
  • [9] COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB AS ADJUVANT TREATMENT FOR RESECTED STAGE IIB/IIC MELANOMA IN GREECE
    Yfantopoulos, N.
    Spanoudi, F.
    Draganigos, A.
    Skroumpelos, A.
    Karokis, A.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S122 - S122
  • [10] COST PER OUTCOME ANALYSIS OF NIVOLUMAB VERSUS DABRAFENIB plus TRAMETINIB AS ADJUVANT THERAPY FOR PATIENTS WITH STAGE IIIB/C BRAF-MUTANT CUTANEOUS MELANOMA IN SPAIN
    Sanchez, Polanco C.
    Moshyk, A.
    Amadi, A.
    Poretta, T.
    Galan, J.
    Vembusubramanian, M.
    Betts, K. A.
    Du, E. X.
    [J]. VALUE IN HEALTH, 2020, 23 : S445 - S445
12345